Acknowledgement
Supported by : National Research Foundation (NRF) of Korea, Chonnam National University Hospital Biomedical Research Institute
References
- Hare, J. M. et al. Comparison of allogeneic vs autologous bone marrowderived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 308, 2369-2379 (2012). https://doi.org/10.1001/jama.2012.25321
- Pittenger, M. F. et al. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143-147 (1999). https://doi.org/10.1126/science.284.5411.143
- Nauta, A. J. & Fibbe, W. E. Immunomodulatory properties of mesenchymal stromal cells. Blood 110, 3499-3506 (2007).
- Choudry, F. et al. A randomized double-blind control study of early intracoronary autologous bone marrow cell infusion in acute myocardial infarction: the REGENERATE-AMI clinical trialdagger. Eur. Heart J. 37, 256-263 (2016). https://doi.org/10.1093/eurheartj/ehv493
- Cho, D. I. et al. The optimization of cell therapy by combinational application with apicidin-treated mesenchymal stem cells after myocardial infarction. Oncotarget 8, 44281-44294 (2017).
- Hahn, J. Y. et al. Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J. Am. Coll. Cardiol. 51, 933-943 (2008). https://doi.org/10.1016/j.jacc.2007.11.040
- Hu, X. et al. Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J. Thorac. Cardiovasc. Surg. 135, 799-808 (2008). https://doi.org/10.1016/j.jtcvs.2007.07.071
- Nahrendorf, M. et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J. Exp. Med. 204, 3037-3047 (2007). https://doi.org/10.1084/jem.20070885
- Leblond, A. L. et al. Systemic and Cardiac Depletion of M2 Macrophage through CSF-1R Signaling Inhibition Alters Cardiac Function Post Myocardial Infarction. PLoS ONE 10, e0137515 (2015). https://doi.org/10.1371/journal.pone.0137515
- Ben-Mordechai, T. et al. Macrophage subpopulations are essential for infarct repair with and without stem cell therapy. J. Am. Coll. Cardiol. 62, 1890-1901 (2013). https://doi.org/10.1016/j.jacc.2013.07.057
- Cho, D. I. et al. Mesenchymal stem cells reciprocally regulate the M1/M2 balance in mouse bone marrow-derived macrophages. Exp. Mol. Med. 46, e70 (2014). https://doi.org/10.1038/emm.2013.135
- Libby, P. Inflammation in atherosclerosis. Nature 420, 868-874 (2002). https://doi.org/10.1038/nature01323
- Han, J. et al. Dual Roles of Graphene Oxide To Attenuate Inflammation and Elicit Timely Polarization of Macrophage Phenotypes for Cardiac Repair. ACS Nano 12, 1959-1977 (2018). https://doi.org/10.1021/acsnano.7b09107
- Jeong, H. Y. et al. 5-Azacytidine modulates interferon regulatory factor 1 in macrophages to exert a cardioprotective effect. Sci. Rep. 5, 15768 (2015). https://doi.org/10.1038/srep15768
- Sager, H. B. et al. Proliferation and recruitment contribute to myocardial macrophage expansion in chronic heart failure. Circ. Res. 119, 853-864 (2016). https://doi.org/10.1161/CIRCRESAHA.116.309001
- Heidt, T. et al. Differential contribution of monocytes to heart macrophages in steady-state and after myocardial infarction. Circ. Res. 115, 284-295 (2014). https://doi.org/10.1161/CIRCRESAHA.115.303567
- Lee, S. J. et al. Enhanced therapeutic and long-term dynamic vascularization effects of human pluripotent stem cell-derived endothelial cells encapsulated in a nanomatrix gel. Circulation 136, 1939-1954 (2017). https://doi.org/10.1161/CIRCULATIONAHA.116.026329
- Sano, T. et al. Impact of cardiac progenitor cells on heart failure and survival in single ventricle congenital heart disease. Circ. Res. 122, 994-1005 (2018). https://doi.org/10.1161/CIRCRESAHA.117.312311
- Pandey, A. C., Lancaster, J. J., Harris, D. T., Goldman, S. & Juneman, E. Cellular therapeutics for heart failure: focus on mesenchymal stem cells. Stem Cells Int. 2017, 640108 (2017).
- Nguyen, P. K., Rhee, J. W. & Wu, J. C. Adult stem cell therapy and heart failure, 2000 to 2016: a systematic review. JAMA Cardiol. 1, 831-841 (2016). https://doi.org/10.1001/jamacardio.2016.2225
- Bolli, R. et al. Rationale and design of the CONCERT-HF trial (Combination of Mesenchymal and c-kit(+) cardiac stem cells as regenerative therapy for heart failure. Circ. Res. 122, 1703-1715 (2018). https://doi.org/10.1161/CIRCRESAHA.118.312978
- Medzhitov, R. & Horng, T. Transcriptional control of the inflammatory response. Nat. Rev. Immunol. 9, 692-703 (2009). https://doi.org/10.1038/nri2634
- Fraccarollo, D., Galuppo, P. & Bauersachs, J. Novel therapeutic approaches to post-infarction remodelling. Cardiovasc. Res. 94, 293-303 (2012). https://doi.org/10.1093/cvr/cvs109
- Harel-Adar, T. et al. Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair. Proc. Natl Acad. Sci. USA 108, 1827-1832 (2011). https://doi.org/10.1073/pnas.1015623108
- Birge, R. B. et al. Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. Cell Death Differ. 23, 962-978 (2016). https://doi.org/10.1038/cdd.2016.11
- Frantz, S. et al. Monocytes/macrophages prevent healing defects and left ventricular thrombus formation after myocardial infarction. FASEB J. 27, 871-881 (2013). https://doi.org/10.1096/fj.12-214049
- van Amerongen, M. J., Harmsen, M. C., van Rooijen, N., Petersen, A. H. & van Luyn, M. J. Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. Am. J. Pathol. 170, 818-829 (2007). https://doi.org/10.2353/ajpath.2007.060547
- de Couto, G. et al. Macrophages mediate cardioprotective cellular postconditioning in acute myocardial infarction. J. Clin. Invest. 125, 3147-3162 (2015). https://doi.org/10.1172/JCI81321
- Nemeth, K. et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 15, 42-49 (2009). https://doi.org/10.1038/nm.1905
- Powell, R. J. et al. Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial. Mol. Ther. 20, 1280-1286 (2012). https://doi.org/10.1038/mt.2012.52
- Ledford, K. J., Zeigler, F. & Bartel, R. L. Ixmyelocel-T, an expanded multicellular therapy, contains a unique population of M2-like macrophages. Stem Cell Res. Ther. 4, 134 (2013). https://doi.org/10.1186/scrt345
- Ledford, K. J., Murphy, N., Zeigler, F. & Bartel, R. L. Potential beneficial effects of ixmyelocel-T in the treatment of atherosclerotic diseases. Stem Cell Res. Ther. 4, 135 (2013). https://doi.org/10.1186/scrt346
- Henry, T. D. et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circ. Res. 115, 730-737 (2014). https://doi.org/10.1161/CIRCRESAHA.115.304554
- Patel, A. N. et al. Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial. Lancet 387, 2412-2421 (2016). https://doi.org/10.1016/S0140-6736(16)30137-4
- Ericson, J. A. et al. Gene expression during the generation and activation of mouse neutrophils: implication of novel functional and regulatory pathways. PLoS ONE 9, e108553 (2014). https://doi.org/10.1371/journal.pone.0108553
- Krausgruber, T. et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat. Immunol. 12, 231-238 (2011). https://doi.org/10.1038/ni.1990
- Takaoka, A. et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434, 243-249 (2005). https://doi.org/10.1038/nature03308
- Courties, G. et al. In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing. J. Am. Coll. Cardiol. 63, 1556-1566 (2014). https://doi.org/10.1016/j.jacc.2013.11.023
Cited by
- Three in a Box: Understanding Cardiomyocyte, Fibroblast, and Innate Immune Cell Interactions to Orchestrate Cardiac Repair Processes vol.6, pp.None, 2018, https://doi.org/10.3389/fcvm.2019.00032
- Turning regenerative technologies into treatment to repair myocardial injuries vol.24, pp.5, 2018, https://doi.org/10.1111/jcmm.14630